Double-Drug attack on tough lung cancer mutation
NCT ID NCT05375994
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their cancer worsen. The trial first finds the safest dose of the combination, then checks how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avutometinib and adagrasib
What this could lead to
If successful, this combination could offer a new treatment option for people with KRAS G12C-mutant lung cancer whose disease has progressed after other therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause side effects or may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Izalontamab brengitecan + osimertinib for EGFR-m NCT07680790
- Chest Tube Suction After Lung Cancer Surgery (NCT02911259)
- Tumor Hypoxia Markers in Head & Neck/Lung Cancer NCT00568490
- Vinorelbine + Atezolizumab for Lung Cancer Trial NCT03801304
- Parecoxib for Pain in Lung Nodule Localization NCT07675473
- ctDNA Test for Cancer Care: NCT07673861
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Cancer Center
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905, United States
-
Medical College Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UCSF Thoracic Oncology
San Francisco, California, 94158, United States
-
University of Colorado Hospital Anschutz Cancer Pavllion
Aurora, Colorado, 80045, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 275514, United States
-
Virginia Cancer Specialists, NEXT Oncology
Fairfax, Virginia, 22031, United States